Related Experiment Video

Updated: May 18, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Hydroxyurea treatment of children with hemoglobin SC disease

Amber M Yates1, Laurence Dedeken, Matthew P Smeltzer

  • 1Baylor College of Medicine and Texas Children's Hematology Center, Houston, Texas, USA. amyates@txch.org

Pediatric Blood & Cancer
|September 6, 2012
PubMed

Insights

Hydroxyurea effectively treats children with severe hemoglobin SC (HbSC) disease, reducing pain crises and hospitalizations. While safe for long-term use, it can cause thrombocytopenia.

Area of Science:

  • Hematology
  • Pediatric medicine
  • Genetic blood disorders

Background:

  • Hemoglobin SC (HbSC) disease is a type of sickle cell disorder.
  • The long-term efficacy of hydroxyurea in HbSC patients is not well-established.
  • Clinically severe HbSC requires effective therapeutic options.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of hydroxyurea in children with severe HbSC.
  • To assess the impact of hydroxyurea on clinical outcomes and laboratory parameters in HbSC patients.

Main Methods:

  • A retrospective study of 15 children with clinically severe HbSC treated with hydroxyurea.
  • Monitoring of clinical outcomes (pain episodes, hospitalizations, acute chest syndrome) and laboratory parameters (MCV, HbF, hemoglobin levels).
  • Assessment of treatment-related side effects.

Main Results:

  • Hydroxyurea significantly increased mean corpuscular volume (MCV) and fetal hemoglobin (HbF).
  • Significant reductions were observed in acute chest syndrome episodes and hospitalizations for pain.
  • No significant effect on overall hemoglobin levels was noted.
  • Thrombocytopenia was the most significant side effect, leading to treatment discontinuation in one patient.

Conclusions:

  • Hydroxyurea demonstrates efficacy in improving clinical outcomes for children with severe HbSC.
  • Long-term hydroxyurea therapy appears safe for HbSC patients, with thrombocytopenia as a notable side effect.
  • Hydroxyurea represents a viable therapeutic option for managing severe HbSC in pediatric patients.

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...